open access
A novel polymer-free everolimus-eluting stent with a nitrogen-doped titanium dioxide film inhibits restenosis and thrombosis in a swine coronary model
Affiliations- Department of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea
- Cardiovascular Research Center, Chonnam National University Hospital, Gwangju, Korea
- Cell and Growth Factor Biotechnology, Ltd., Seoul, Republic of Korea
open access
Abstract
Background: Short-term outcomes regarding the safety and efficacy of a polymer-free everolimus-eluting stent (EES) with a nitrogen-doped titanium dioxide (N-TiO2) film in a swine coronary model have been reported. However, the long-term results of the use of this type of stent have not yet been evaluated or compared to those of other polymer-free coronary stents. Therefore, this study aimed to determine the mid- to long-term safety and efficacy of a polymer-free EES with an N-TiO2 film in a swine coronary model.
Methods: Polymer-free EES with N-TiO2 films (n = 30) and polymer-free sirolimus-eluting stents (SES; n = 30) were implanted in 30 pigs. Quantitative coronary analysis and optical coherence tomography were conducted immediately and at 1 (quantitative coronary analysis only), 3, and 6 months after stenting. Histopathologic examinations were performed at 1, 3, and 6 months after stenting.
Results: The polymer-free EES group had a lower percentage of neointimal growth than the polymer-free SES group at 3 months (22.5% ± 11.4% vs. 32.1% ± 12.3%; p < 0.001). The polymer-free EES group had a lower fibrin score than the polymer-free SES group at 1 month (1.9 ± 0.45 vs. 2.5 ± 0.54; p = 0.001). The re-endothelialization rates were similar between groups. The polymer-free EES group had a lower percentage of the area of stenosis than the polymer-free SES group throughout the follow-up period.
Conclusions: The novel polymer-free EES with an N-TiO2 film has superior safety and efficacy than the polymer-free SES at the 6-month follow-up in a swine model.
Abstract
Background: Short-term outcomes regarding the safety and efficacy of a polymer-free everolimus-eluting stent (EES) with a nitrogen-doped titanium dioxide (N-TiO2) film in a swine coronary model have been reported. However, the long-term results of the use of this type of stent have not yet been evaluated or compared to those of other polymer-free coronary stents. Therefore, this study aimed to determine the mid- to long-term safety and efficacy of a polymer-free EES with an N-TiO2 film in a swine coronary model.
Methods: Polymer-free EES with N-TiO2 films (n = 30) and polymer-free sirolimus-eluting stents (SES; n = 30) were implanted in 30 pigs. Quantitative coronary analysis and optical coherence tomography were conducted immediately and at 1 (quantitative coronary analysis only), 3, and 6 months after stenting. Histopathologic examinations were performed at 1, 3, and 6 months after stenting.
Results: The polymer-free EES group had a lower percentage of neointimal growth than the polymer-free SES group at 3 months (22.5% ± 11.4% vs. 32.1% ± 12.3%; p < 0.001). The polymer-free EES group had a lower fibrin score than the polymer-free SES group at 1 month (1.9 ± 0.45 vs. 2.5 ± 0.54; p = 0.001). The re-endothelialization rates were similar between groups. The polymer-free EES group had a lower percentage of the area of stenosis than the polymer-free SES group throughout the follow-up period.
Conclusions: The novel polymer-free EES with an N-TiO2 film has superior safety and efficacy than the polymer-free SES at the 6-month follow-up in a swine model.
Keywords
drug-eluting stent, optical coherence tomography, polymer, restenosis, titanium dioxide
Supp./Additional Files (1)
About this articleTitle
A novel polymer-free everolimus-eluting stent with a nitrogen-doped titanium dioxide film inhibits restenosis and thrombosis in a swine coronary model
Journal
Issue
Article type
Original Article
Published online
2023-01-30
Page views
639
Article views/downloads
90
DOI
10.5603/CJ.a2023.0006
Pubmed
Keywords
drug-eluting stent
optical coherence tomography
polymer
restenosis
titanium dioxide
Authors
Dae Young Hyun
Xiongyi Han
Dae Sung Park
Munki Kim
Jun Kyu Park
Kyung Hoon Cho
Doo Sun Sim
Young Joon Hong
Youngkeun Ahn
Myung Ho Jeong
References (27)- Brophy JM, Belisle P, Joseph L, et al. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med. 2003; 138(10): 777–786.
- Bønaa KH, Mannsverk J, Wiseth R, et al. NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016; 375(13): 1242–1252.
- Moses JW, Leon MB, Popma JJ, et al. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349(14): 1315–1323.
- Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004; 109(6): 701–705.
- Torrado J, Buckley L, Durán A, et al. Restenosis, stent thrombosis, and bleeding complications: navigating between Scylla and Charybdis. J Am Coll Cardiol. 2018; 71(15): 1676–1695.
- Ijichi T, Nakazawa G, Torii S, et al. Comparisons of early vascular reactions in biodegradable and durable polymer-based drug-eluting stents in the porcine coronary artery. PLoS One. 2019; 14(1): e0209841.
- Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015; 373(21): 2038–2047.
- Song SJ, Jung K, Park Y, et al. Nitrogen-doped TiO2 films as drug-binding matrices for the preparation of drug-eluting stents. J Mater Chem. 2011; 21(22): 8169.
- Song SJ, Park Y, Park J, et al. Preparation of a drug-eluting stent using a TiO2 film deposited by plasma enhanced chemical vapour deposition as a drug-combining matrix. J Mater Chem. 2010; 20(23): 4792.
- Park DS, Bae IH, Jeong MHo, et al. In vitro and in vivo evaluation of a novel polymer-free everolimus-eluting stent by nitrogen-doped titanium dioxide film deposition. Mater Sci Eng C Mater Biol Appl. 2018; 91: 615–623.
- Sim DS, Jeong MHo, Park DS, et al. A novel polymer-free drug-eluting stent coated with everolimus using nitrogen-doped titanium dioxide film deposition in a porcine coronary restenosis model. Int J Cardiol. 2016; 222: 436–440.
- Won H, Kim JS, Shin DH, et al. Serial changes of neointimal tissue after everolimus-eluting stent implantation in porcine coronary artery: an optical coherence tomography analysis. Biomed Res Int. 2014; 2014: 851676.
- Byrne RA, Mehilli J, Iijima R, et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J. 2009; 30(8): 923–931.
- Massberg S, Byrne RA, Kastrati A, et al. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation. 2011; 124(5): 624–632.
- Kufner S, Sorges J, Mehilli J, et al. Randomized trial of polymer-free sirolimus- and probucol-eluting stents versus durable polymer zotarolimus-eluting stents: 5-year results of the ISAR-TEST-5 trial. JACC Cardiovasc Interv. 2016; 9(8): 784–792.
- Torii S, Cheng Qi, Mori H, et al. Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer-free stents. EuroIntervention. 2019; 14(16): 1685–1693.
- Otsuka F, Cheng Qi, Yahagi K, et al. Acute thrombogenicity of a durable polymer everolimus-eluting stent relative to contemporary drug-eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model. JACC Cardiovasc Interv. 2015; 8(9): 1248–1260.
- Chen W, Habraken TCJ, Hennink WE, et al. Polymer-Free drug-eluting stents: an overview of coating strategies and comparison with polymer-coated drug-eluting stents. Bioconjug Chem. 2015; 26(7): 1277–1288.
- De Scheerder I, Verbeken E, Van Humbeeck J. Metallic surface modification. Semin Interv Cardiol. 1998; 3(3-4): 139–144.
- Dibra A, Kastrati A, Mehilli J, et al. Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a randomized double-blind controlled trial. Catheter Cardiovasc Interv. 2005; 65(3): 374–380.
- Palmaz JC, Benson A, Sprague EA. Influence of surface topography on endothelialization of intravascular metallic material. J Vasc Interv Radiol. 1999; 10(4): 439–444.
- Kolandaivelu K, Bailey L, Buzzi S, et al. Ultra-hydrophilic stent platforms promote early vascular healing and minimise late tissue response: a potential alternative to second-generation drug-eluting stents. EuroIntervention. 2017; 12(17): 2148–2156.
- Hezi-Yamit A, Sullivan C, Wong J, et al. Impact of polymer hydrophilicity on biocompatibility: implication for DES polymer design. J Biomed Mater Res A. 2009; 90(1): 133–141.
- Habib A, Karmali V, John MC, et al. Everolimus-eluting stents improve vascular response in a diabetic animal model. Circ Cardiovasc Interv. 2014; 7(4): 526–532.
- Buiten R, Ploumen E, Zocca P, et al. Thin, very thin, or ultrathin strut biodegradable or durable polymer-coated drug-eluting stents. JACC: Cardiovasc Interv. 2019; 12(17): 1650–1660.
- Jensen LO, Thayssen P, Christiansen EH, et al. Safety and efficacy of everolimus- versus sirolimus-eluting stents: 5-year results from SORT OUT IV. J Am Coll Cardiol. 2016; 67(7): 751–762.
- Cho KH, Jeong MHo, Park DS, et al. Preclinical evaluation of a novel polymer-free everolimus-eluting stent in a mid-term porcine coronary restenosis model. J Korean Med Sci. 2021; 36(40): e259.
